An innovation-driven global pharmaceutical company, Glenmark Pharmaceuticals Limited (Glenmark) has launched the novel fixed-dose combination (FDC) drug – Indacaterol + Mometasone in India, for patients suffering from uncontrolled asthma.
Glenmark has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily. Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist, and Mometasone Furoate, an inhaled corticosteroid that is approved by the Drug Controller General of India (DCGI).
While speaking on the development, Alok Malik, Group Vice-President & Head, India Formulations, Glenmark Pharmaceuticals Limited, said, this novel fixed-dose combination Indamet is the first of its kind in India. It offers a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.
